Orexin 2 receptor agonists are drugs that stimulate a specific receptor in the brain involved in wakefulness; think of them as turning up a targeted “wake” switch to help people stay alert. For investors, these medicines matter because successful clinical trial results or regulatory approval can create a new treatment market for sleep disorders and affect the value, revenue prospects, and risk profile of companies developing them.
idiopathic hypersomniamedical
A chronic sleep disorder that causes extreme daytime sleepiness and prolonged, unrefreshing sleep despite adequate night sleep, with no identifiable medical or neurological cause. Think of it like a phone battery that won’t hold charge: sufferers remain tired and less productive even after long rest. For investors, idiopathic hypersomnia matters because it creates demand for treatments, diagnostics and supportive services, influencing market opportunities and regulatory pathways in sleep medicine.
adhdmedical
Attention-deficit/hyperactivity disorder (ADHD) is a common brain condition that makes it hard for people to focus, control impulses, and sit still—like having a car with strong accelerator and less-effective brakes for attention and activity. For investors, ADHD matters because it drives demand for medications, therapy, digital tools, and education supports, affects workplace productivity and healthcare costs, and is subject to regulatory approvals and insurance coverage decisions that influence market opportunities.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended June 30, 2026. To view the detailed second quarter 2026 earnings press release and presentation, please visit the company’s investor relations website at https://investor.alkermes.com.
Alkermes will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) today, to discuss these financial results and expectations, and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes’ website at https://investor.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. In addition, a replay of the conference call may be accessed by visiting Alkermes’ website.
About Alkermes plc
Alkermes plc, a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Alkermes’ pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.
